BTIG analyst Sean Lavin maintained a Buy rating on Valeritas (VLRX – Research Report) yesterday and set a price target of $14. The company’s shares closed yesterday at $3.23, close to its 52-week low of $2.10.
According to TipRanks.com, Lavin is a 4-star analyst with an average return of 5.9% and a 56.6% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Currently, the analyst consensus on Valeritas is a Moderate Buy with an average price target of $27.
The company has a one-year high of $41.60 and a one-year low of $2.10. Currently, Valeritas has an average volume of 1.31M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Valeritas Holdings, Inc. is a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with diabetes. It offers products under the V-Go brand. V-Go Disposable Insulin Delivery Device, is used by patients with type 2 diabetes to maintain target blood glucose goals.